Disclosures for "Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial"
-
Miss Kwan has nothing to disclose.
-
Miss Phan has nothing to disclose.
-
The institution of Dr. Mansur has received research support from CIHR. The institution of Dr. Mansur has received research support from PSI. The institution of Dr. Mansur has received research support from Baszucki Brain Research Fund.
-
Dr. Rosenblat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Braxia.
-
Mr. Guo has nothing to disclose.
-
Ms. Le has nothing to disclose.
-
Miss Teopiz has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Braxia Scientific Corp..
-
Ms. Ceban has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brain and Cognition Discovery Foundation.
-
Ms. Bailey has received personal compensation for serving as an employee of Brain and Cognition Discovery Foundation.
-
Mr. Ramachandra has nothing to disclose.
-
Mr. Di Vincenzo has received personal compensation in the range of $0-$499 for serving as a Peer Reviewer with Expert Opinion On Pharmacotherapy.
-
Mr. Badulescu has nothing to disclose.
-
Dr. Drzadzewski has received research support from Brain and Cognition Discovery Foundation.
-
Dr. McIntyre has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals,Viatris, Abbvie, Atai Life Sciences. Dr. McIntyre has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals,Viatris, Abbvie, Atai Life Sciences. Dr. McIntyre has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals,Viatris, Abbvie, Atai Life Sciences. Dr. McIntyre has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals,Viatris, Abbvie, Atai Life Sciences. Dr. McIntyre has received research support from research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute. Dr. McIntyre has received personal compensation in the range of $100,000-$499,999 for serving as a Chief Executive Officer with Braxia Scientific Corp.